PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cochrane Database Syst Rev
Hoofdauteurs: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Ltd 2020
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items